Study of IBI354 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
A phase 3 trial testing IBI354 in ovarian cancer, active and no longer recruiting.
Overview
Study of IBI354 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer is a phase 3 interventional study registered as NCT06834672, led by Innovent Biologics (Suzhou), and active but no longer recruiting when checked on 2026-09-11. Official title: A Multicenter, Randomised, Open-label Phase III Study of IBI354 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer. Planned enrolment is 450 participants (estimated). The study started in 2025-03-17 and primary completion is expected in 2027-12-28. No results have been posted on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- TrialIBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer
Shares IBI354, Innovent Biologics and the tag ctgov-ingest.
- TrialA Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002)
Shares Innovent Biologics and the tag ctgov-ingest.
- TrialA Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment
Shares Innovent Biologics and the tag ctgov-ingest.
- TrialA Study of IMP4297 as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer
Shares Ovarian cancer and the tag ctgov-ingest.
- TrialOregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery
Shares Ovarian cancer and the tag ctgov-ingest.
- TrialA Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Shares Ovarian cancer and the tag ctgov-ingest.
- TrialAZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
Shares Ovarian cancer and the tag ctgov-ingest.
- TrialSHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer
Shares Ovarian cancer and the tag ctgov-ingest.